These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32344823)

  • 1. The Effects of Human BDH2 on the Cell Cycle, Differentiation, and Apoptosis and Associations with Leukemia Transformation in Myelodysplastic Syndrome.
    Yang WC; Lin SF; Wang SC; Tsai WC; Wu CC; Wu SC
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia.
    Yang WC; Tsai WC; Lin PM; Yang MY; Liu YC; Chang CS; Yu WH; Lin SF
    J Biomed Sci; 2013 Aug; 20(1):58. PubMed ID: 23941109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.
    Nian Q; Xiao Q; Wang L; Luo J; Chen LP; Yang ZS; Liu L
    Int J Mol Med; 2014 Apr; 33(4):856-62. PubMed ID: 24535175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
    Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
    Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
    Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
    BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
    Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
    Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53.
    Wang L; Luo J; Nian Q; Xiao Q; Yang Z; Liu L
    Hematology; 2014 Jun; 19(4):225-31. PubMed ID: 24074450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
    Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.
    Li S; Zhao G; Wu W; Li N; Wang Q; Wang W; Song X; Wang X
    Clin Exp Med; 2023 Dec; 23(8):4649-4664. PubMed ID: 37930606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
    Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
    Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
    Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
    Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
    Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
    Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Matrix metalloproteinase-9 in plasma of bone marrow aspirates of patients with acute myeloid leukemia and myelodysplastic syndrome].
    Lesnichenko IF; Kostroma II; Gritsaev SV; Chechetkin AV; Abdulkadyrov KM
    Vopr Onkol; 2016; 62(1):101-3. PubMed ID: 30444586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoiesis-related microRNA expression in myelodysplastic syndromes.
    Pons A; Nomdedeu B; Navarro A; Gaya A; Gel B; Diaz T; Valera S; Rozman M; Belkaid M; Montserrat E; Monzo M
    Leuk Lymphoma; 2009 Nov; 50(11):1854-9. PubMed ID: 19883312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAB27B inhibits proliferation and promotes apoptosis of leukemic cells via 3-Hydroxy butyrate dehydrogenase 2 (BDH2).
    Meng C; Huang L; Fu X; Wu B; Lin L
    Bioengineered; 2022 Mar; 13(3):5103-5112. PubMed ID: 35164665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.